['relapsed/refractory b-precursor acute lymphoblastic leukemia']
['blinatumomab', 'standard of care chemotherapy']

        -  Subjects with Philadelphia negative B-precursor ALL, with any of the following:

               -  refractory to primary induction therapy or refractory to salvage therapy,

               -  in untreated first relapse with first remission duration <12 months

               -  in untreated second or greater relapse

               -  relapse at any time after allogeneic HSCT

          -  Subject has received intensive combination chemotherapy for the treatment of ALL for
             initial treatment or subsequent salvage therapy.

          -  Greater than 5% blasts in the bone marrow

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

        Exclusion Criteria

          -  Malignancy other than ALL within 5 years before blinatumomab treatment, except for
             adequately treated selected cancers without evidence of disease

          -  Diagnosis of Burkitt's leukemia according to World Health Organization classification,
             or human immunodeficiency virus (HIV), Hepatitis B or C, or other clinically
             significant disorder

          -  Current relevant central nervous system (CNS) pathology or known or suspected CNS
             involvement

          -  Isolated extramedullary disease

          -  Current autoimmune disease or history of autoimmune disease with potential CNS
             involvement

          -  Autologous HSCT within 6 weeks or allogeneic HSCT within 12 weeks before blinatumomab
             treatment, or eligibility for allogeneic HSCT at the time of enrollment

          -  Active acute grade 2 to 4 graft versus host disease (GvHD) according to Glucksberg et
             al (1974) criteria that required systemic treatment to prevent or treat GvHD 2 weeks
             before blinatumomab treatment

          -  Known exclusion criteria to investigator choice of SOC chemotherapy (per package
             insert)

          -  Cancer chemotherapy or radiotherapy with 2 weeks, or immunotherapy (included CD19
             therapy) within 4 weeks of protocol-specified therapy

          -  Abnormal laboratory values (alanine or aspartate transaminase [ALT or AST] or alkaline
             phosphatase [ALP] ≥ 5 × upper limit of normal [ULN]; total bilirubin or creatinine ≥
             1.5 × ULN), or calculated creatinine clearance < 60 mL/min.
      